Patents by Inventor Lene Schantz HARLOW

Lene Schantz HARLOW has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES DIRECTED AGAINST CD3 AND CD20 AND THEIR USES
    Publication number: 20220411505
    Abstract: The present invention relates to improved pharmaceutical compositions and dosage unit forms of bispecific CD3×CD20 antibodies and to routes of administration.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 29, 2022
    Inventors: Jesper VALBJOERN, Lene Schantz HARLOW, Jacob Dahlqvist CLAUSEN, Mette Hamborg JENSEN, Christian CIMANDER, Jesper PASS, Peter Juul MADSEN, Shan REN, Maria Anna Cecilia WAHLBOM, Bolette BJERREGAARD
  • PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES DIRECTED AGAINST CD3 AND CD20 AND THEIR USES
    Publication number: 20210032358
    Abstract: The present invention relates to pharmaceutical compositions and dosage unit forms of bispecific CD3xCD20 antibodies and to routes of administration.
    Type: Application
    Filed: February 8, 2019
    Publication date: February 4, 2021
    Inventors: Jesper VALBJOERN, Lene Schantz HARLOW, Jacob Dahlqvist CLAUSEN, Mette Hamborg JENSEN, Christian CIMANDER, Peter Juul MADSEN
  • THERAPEUTIC ANTIBODIES BASED ON MUTATED IGG HEXAMERS
    Publication number: 20200247897
    Abstract: The present invention relates to formulation of antibodies. The invention relates in particular to pharmaceutical compositions comprising an antibody molecule of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding.
    Type: Application
    Filed: June 7, 2018
    Publication date: August 6, 2020
    Inventors: Mette Hamborg JENSEN, Lene Schantz HARLOW, Andrew HAGARMAN, Cale HALBLEIB
  • FORMULATION FOR ANTIBODY AND DRUG CONJUGATE THEREOF
    Publication number: 20190030180
    Abstract: Disclosed herein are surfactant free antibody and antibody-drug-conjugate (ADC) formulations for anti-AXL antibodies and ADCs, including aqueous formulations, lyophilized formulations, and reconstituted formulations, as well as related processes and uses. The formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some formulations comprise histidine and mannitol.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 31, 2019
    Inventors: Lene Schantz HARLOW, Timothy Warren PAUL, Brendan M. MAYHUGH, Kelly Ann ROBY, Gregory Allan SACHA, Xiaona JING, Andrew HAGARMAN, Cale HALBLEIB